A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis

Table Omitted - see PDF ] Table 1 Characteristics of patients who were either administered tocilizumab at different intervals or methotrexate 3-Week group (n?=?10) 4-Week group (n?=?10) 5-Week group (n?=?10) Control group (n?=?10) P value Sex (female, n/total n, %) 9/10, 90% 9/10, 90% 8/10, 80% 8/10, 80% 0.85 Age (years) 55.3 (14.8) 65.0 (9.9) 62.0 (10.6) 66.7 (11.0) 0.27 RA duration (months) 101.5 (86.5) 68.5 (74.6) 116.5 (92.5) 81.9 (78.7) 0.35 Tocilizumab duration (months) 27.1 (20.7) 11.9 (9.2) 39.6 (12.1) - <0.01* RF positive (n, %) 7/10, 70% 9/10, 90% 9/10, 90% 5/10, 50% 0.12 ACPA pos... Mehr ...